NCT06337760 YOUNg Adults With Gastro-inteSTinal (GI) and nEuroendocrine canceRs.
| NCT ID | NCT06337760 |
| Status | Recruiting |
| Phase | — |
| Sponsor | European Institute of Oncology |
| Condition | Neuroendocrine Neoplasm |
| Study Type | OBSERVATIONAL |
| Enrollment | 90 participants |
| Start Date | 2023-03-10 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 90 participants in total. It began in 2023-03-10 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The objective of the study is to create a common and unique platform for the acquisition of biological samples and, subsequently, the possible identification of predictive and prognostic biomarkers for young adults with gastrointestinal and neuroendocrine cancers.The definition "adolescent and young adults (AYA)" covers a broad group of patients ranging from the upper limit of the paediatric competence to the youngest patients usually considered and treated as adults. However, a well-defined and universally accepted age range is still not established. Young adults with cancer have distinct epidemiological, biological, and clinical characteristics, as well as special medical and psychosocial needs that are often unmet. In consideration of their poor representation in clinical studies, as well as the rarer, albeit increasing, frequency at an epidemiological level, knowledge of the risk factors associated with cancers in young adults is very poor. It is therefore of fundamental importance to focus attention on this specific cohort of patients, in order to describe in ever more detail any specific biomolecular aspects, and make full use of the pharmacological resources currently available.
Eligibility Criteria
Inclusion Criteria: * Age at diagnosis from18 to 39 years of age * Carcinoma (without limitations for histologic subtypes) from any primary sites: esophagus, stomach, pancreas, biliary tract, liver, small bowel, colon, rectum, anus and cancer of unknown origin * Neuroendocrine neoplasm (NEN) from Gastroenteropancreatic GEP or lung/thymus origin * Tumors at any stage at the first visit * Tumors of any grade * Histological diagnosis obtained within two years from the time of enrollment or willingness to undergo bioptic procedure for diagnosis Exclusion Criteria: * Age at diagnosis \> 39 years old
Contact & Investigator
Francesca Spada, MD
PRINCIPAL INVESTIGATOR
Istituto Europeo di Oncologia
Frequently Asked Questions
Who can join the NCT06337760 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 39 Years, studying Neuroendocrine Neoplasm. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06337760 currently recruiting?
Yes, NCT06337760 is actively recruiting participants. Contact the research team at divisione.gastrointestinale@ieo.it for enrollment information.
Where is the NCT06337760 trial being conducted?
This trial is being conducted at Milan, Italy.
Who is sponsoring the NCT06337760 clinical trial?
NCT06337760 is sponsored by European Institute of Oncology. The principal investigator is Francesca Spada, MD at Istituto Europeo di Oncologia. The trial plans to enroll 90 participants.